Recent Updates
Recently added Catalysts
PRCT Positive Sentiment

PROCEPT BioRobotics® to Attend the Baird 2026 Global Healthcare Conference on September 15, 2026

Key Takeaway: PROCEPT BioRobotics Corporation will participate in the Baird 2026 Global Healthcare Conference on September 15, 2026. Management will present and host investor meetings in New York City. The company focuses on surgical robotics and has developed the AQUABEAM and HYDROS Robotic Systems for urology treatments, particularly for BPH.

Market Sentiment Analysis

POSITIVE FACTORS

  • PROCEPT BioRobotics is advancing patient care with innovative solutions.
  • The company is presenting at a significant healthcare conference.
  • It has a strong clinical evidence base with 250 peer-reviewed publications.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~25 mo
Minimal dilution risk
Lead asset
PRO 2000
Phase 1 · HIV Infections

Full Press Release Details

SAN JOSE, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced members of management will present and host investor meetings at the upcoming Baird 2026 Global Healthcare Conference in New York City on Tuesday, September 15.
To view the presentation or schedule a meeting with management, please reach out to your Baird representative.
About PROCEPT BioRobotics Corporation PROCEPT BioRobotics is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The Company manufactures the AQUABEAM ® and HYDROS ® Robotic Systems. The HYDROS Robotic System is the only AI-powered, robotic technology that delivers Aquablation therapy. PROCEPT BioRobotics designed Aquablation therapy to deliver effective, safe, and durable outcomes for males suffering from lower urinary tract symptoms or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience. In addition to its leadership in BPH treatment, the Company is pursuing clinical research initiatives in prostate cancer utilizing investigational applications of its robotic and AI-enabled technologies. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. The Company has developed a significant and growing body of clinical evidence with approximately 250 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy.

Investor Contact: Marissa Bych Managing Director Gilmartin Group LLC Marissa@gilmartinir.com

Frequently Asked Questions

When is the Baird 2026 Global Healthcare Conference?

The conference will take place on September 15, 2026.

What is PROCEPT BioRobotics known for?

The company specializes in surgical robotics and urology solutions.

What technologies does PROCEPT BioRobotics offer?

They offer the AQUABEAM and HYDROS Robotic Systems for urology.

How many peer-reviewed publications support Aquablation therapy?

There are approximately 250 peer-reviewed publications supporting it.

Last updated: Aug 17, 2026